FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:GGNBP2-NEBL

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: GGNBP2-NEBL
FusionPDB ID: 33031
FusionGDB2.0 ID: 33031
HgeneTgene
Gene symbol

GGNBP2

NEBL

Gene ID

79893

10529

Gene namegametogenetin binding protein 2nebulette
SynonymsDIF-3|DIF3|LCRG1|LZK1|ZFP403|ZNF403C10orf113|LASP2|LNEBL|bA165O3.1
Cytomap

17q12

10p12.31

Type of geneprotein-codingprotein-coding
Descriptiongametogenetin-binding protein 2C3HC4-type zinc finger proteinlaryngeal carcinoma related gene 1laryngeal carcinoma-related protein 1zinc finger protein 403nebuletteLIM and SH3 protein 2LIM-nebuletteactin-binding Z-disk protein
Modification date2020031320200313
UniProtAcc

Q9H3C7

Main function of 5'-partner protein: FUNCTION: May be involved in spermatogenesis.

O76041

Main function of 5'-partner protein: FUNCTION: Binds to actin and plays an important role in the assembly of the Z-disk. May functionally link sarcomeric actin to the desmin intermediate filaments in the heart muscle sarcomeres (PubMed:27733623). Isoform 2 might play a role in the assembly of focal adhesion (PubMed:15004028). {ECO:0000269|PubMed:15004028, ECO:0000269|PubMed:27733623}.
Ensembl transtripts involved in fusion geneENST idsENST00000304718, ENST00000485685, 
ENST00000377119, ENST00000464278, 
ENST00000377122, ENST00000377159, 
ENST00000417816, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score6 X 7 X 6=25212 X 11 X 6=792
# samples 613
** MAII scorelog2(6/252*10)=-2.0703893278914
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(13/792*10)=-2.60698880705116
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: GGNBP2 [Title/Abstract] AND NEBL [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: GGNBP2 [Title/Abstract] AND NEBL [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)GGNBP2(34901666)-NEBL(21101869), # samples:3
Anticipated loss of major functional domain due to fusion event.GGNBP2-NEBL seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
GGNBP2-NEBL seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
GGNBP2-NEBL seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
GGNBP2-NEBL seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:34901666/chr10:21101869)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across GGNBP2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across NEBL (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000304718GGNBP2chr1734901666+ENST00000377122NEBLchr1021101869-68824092171107296
ENST00000304718GGNBP2chr1734901666+ENST00000417816NEBLchr1021101869-2706409217864215
ENST00000304718GGNBP2chr1734901666+ENST00000377159NEBLchr1021101869-1141409217864215

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000304718ENST00000377122GGNBP2chr1734901666+NEBLchr1021101869-0.0003264630.9996736
ENST00000304718ENST00000417816GGNBP2chr1734901666+NEBLchr1021101869-0.0008541170.99914587
ENST00000304718ENST00000377159GGNBP2chr1734901666+NEBLchr1021101869-0.0036267890.99637324

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for GGNBP2-NEBL

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
GGNBP2chr1734901666NEBLchr102110186940964RRQIPLYIDDTLTVKYHEDFEKTKGR

Top

Potential FusionNeoAntigen Information of GGNBP2-NEBL in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
GGNBP2-NEBL_34901666_21101869.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B18:01DDTLTVKY0.9970.5683816
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B57:03LTVKYHEDF0.96170.98921120
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B15:02YIDDTLTVKY0.96540.6707616
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B35:04IPLYIDDTLTV0.97840.9057314
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B35:02IPLYIDDTLTV0.97840.9057314
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B35:03IPLYIDDTLTV0.9760.8556314
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C05:09YIDDTLTV10.9409614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C04:07YIDDTLTV10.6369614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C04:10YIDDTLTV10.634614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C08:15YIDDTLTV0.99990.9399614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C04:06YIDDTLTV0.99920.8287614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C04:14YIDDTLTV0.99650.5634614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-A02:07YIDDTLTV0.99260.5555614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C08:13YIDDTLTV0.9850.9271614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C08:04YIDDTLTV0.9850.9271614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C08:03YIDDTLTV0.95820.9592614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C04:10LYIDDTLTV0.97440.5702514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C04:14LYIDDTLTV0.72330.6316514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:05LYIDDTLTV0.43940.9571514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C12:16LYIDDTLTV0.42390.9328514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:67LYIDDTLTV0.28290.8607514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:80LYIDDTLTV0.28290.8607514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:46LYIDDTLTV0.27220.7069514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:10LYIDDTLTV0.25650.9342514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:19LYIDDTLTV0.23980.56514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:29LYIDDTLTV0.2210.8667514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:13LYIDDTLTV0.15520.8042514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:27LYIDDTLTV0.11260.9162514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:95LYIDDTLTV0.08390.6174514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C05:09YIDDTLTVKY0.99980.7605616
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B15:05YIDDTLTVKY0.97460.6068616
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B15:21YIDDTLTVKY0.96280.6068616
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B15:31YIDDTLTVKY0.95850.6212616
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B15:21LYIDDTLTVKY0.99920.6304516
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B35:12IPLYIDDTLTV0.97840.9057314
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C18:01YIDDTLTV10.658614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C04:03YIDDTLTV10.6829614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C04:01YIDDTLTV10.6369614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C05:01YIDDTLTV10.9409614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C08:02YIDDTLTV0.99990.9399614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C04:04YIDDTLTV0.99880.8028614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B18:04DDTLTVKY0.9980.6034816
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B18:07DDTLTVKY0.99750.5124816
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B18:06DDTLTVKY0.99720.56816
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B18:05DDTLTVKY0.9970.5683816
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B18:03DDTLTVKY0.99530.5501816
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C08:01YIDDTLTV0.95820.9592614
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C18:01LYIDDTLTV0.95440.6335514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B18:04IDDTLTVKY0.93720.783716
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B18:08IDDTLTVKY0.88580.5406716
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B18:06IDDTLTVKY0.83730.7692716
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C04:04LYIDDTLTV0.81170.8025514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B18:11IDDTLTVKY0.79650.6547716
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C06:02LYIDDTLTV0.79430.9811514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C06:17LYIDDTLTV0.79430.9811514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C06:06LYIDDTLTV0.57470.9375514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C14:03LYIDDTLTV0.52120.9103514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C14:02LYIDDTLTV0.52120.9103514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C03:67LYIDDTLTV0.38960.9792514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:02LYIDDTLTV0.28290.8607514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:17LYIDDTLTV0.2070.9335514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C06:08LYIDDTLTV0.11840.9707514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:22LYIDDTLTV0.11460.6946514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:04LYIDDTLTV0.10230.9278514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C07:01LYIDDTLTV0.08440.5805514
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C05:01YIDDTLTVKY0.99980.7605616
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B15:11YIDDTLTVKY0.97990.5738616
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B15:08YIDDTLTVKY0.97910.5622616
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B15:20YIDDTLTVKY0.97660.6939616
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B35:23YIDDTLTVKY0.96320.6417616
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B35:20YIDDTLTVKY0.96030.7084616
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C14:02LYIDDTLTVKY0.99620.8588516
GGNBP2-NEBLchr1734901666chr1021101869409HLA-C14:03LYIDDTLTVKY0.99620.8588516
GGNBP2-NEBLchr1734901666chr1021101869409HLA-B35:09IPLYIDDTLTV0.97840.9057314

Top

Potential FusionNeoAntigen Information of GGNBP2-NEBL in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
GGNBP2-NEBL_34901666_21101869.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0301QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0301RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0305QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0307QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0310QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0310RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0310RRQIPLYIDDTLTVK015
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0313QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0313RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0315QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0318QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0318RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0320QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0320RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0322QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0322RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0324QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0326QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0326RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0326RRQIPLYIDDTLTVK015
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0328QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0328RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0330QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0330RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0332QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0332RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0334QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0334RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0336QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0336RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0338QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0338RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0340QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0342QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0342RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0342RRQIPLYIDDTLTVK015
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0342IPLYIDDTLTVKYHE318
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0344QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0344RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0346QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0346RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0348QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0348RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0350QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0350RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0352QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0352RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0354QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0354RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0422QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-0422RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-1107QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-1476QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-1476RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-1476RRQIPLYIDDTLTVK015
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-1479QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-1479RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-1479RRQIPLYIDDTLTVK015
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-1525QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB1-1525RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0101QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0101RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0101RRQIPLYIDDTLTVK015
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0104QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0104RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0104RRQIPLYIDDTLTVK015
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0105QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0105RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0105RRQIPLYIDDTLTVK015
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0108QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0108RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0108RRQIPLYIDDTLTVK015
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0109QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0111QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0111RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0111RRQIPLYIDDTLTVK015
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0112QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0112RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0112RRQIPLYIDDTLTVK015
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0113QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0113RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0113RRQIPLYIDDTLTVK015
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0114QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0114RQIPLYIDDTLTVKY116
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0114RRQIPLYIDDTLTVK015
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0204QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB3-0303QIPLYIDDTLTVKYH217
GGNBP2-NEBLchr1734901666chr1021101869409DRB5-0106TLTVKYHEDFEKTKG1025

Top

Fusion breakpoint peptide structures of GGNBP2-NEBL

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
10671YIDDTLTVKYHEDFGGNBP2NEBLchr1734901666chr1021101869409

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of GGNBP2-NEBL

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN10671YIDDTLTVKYHEDF-7.15543-7.26883
HLA-B14:023BVN10671YIDDTLTVKYHEDF-4.77435-5.80965
HLA-B52:013W3910671YIDDTLTVKYHEDF-6.80875-6.92215
HLA-B52:013W3910671YIDDTLTVKYHEDF-4.20386-5.23916
HLA-A11:014UQ210671YIDDTLTVKYHEDF-7.5194-8.5547
HLA-A11:014UQ210671YIDDTLTVKYHEDF-6.9601-7.0735
HLA-A24:025HGA10671YIDDTLTVKYHEDF-7.52403-7.63743
HLA-A24:025HGA10671YIDDTLTVKYHEDF-5.82433-6.85963
HLA-B27:056PYJ10671YIDDTLTVKYHEDF-3.28285-4.31815
HLA-B44:053DX810671YIDDTLTVKYHEDF-5.91172-6.94702
HLA-B44:053DX810671YIDDTLTVKYHEDF-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of GGNBP2-NEBL

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
GGNBP2-NEBLchr1734901666chr10211018691120LTVKYHEDFCTGACGGTAAAATACCATGAAGATTTT
GGNBP2-NEBLchr1734901666chr1021101869314IPLYIDDTLTVATTCCCCTCTACATAGACGACACCCTGACGGTA
GGNBP2-NEBLchr1734901666chr1021101869514LYIDDTLTVCTCTACATAGACGACACCCTGACGGTA
GGNBP2-NEBLchr1734901666chr1021101869516LYIDDTLTVKYCTCTACATAGACGACACCCTGACGGTAAAATAC
GGNBP2-NEBLchr1734901666chr1021101869614YIDDTLTVTACATAGACGACACCCTGACGGTA
GGNBP2-NEBLchr1734901666chr1021101869616YIDDTLTVKYTACATAGACGACACCCTGACGGTAAAATAC
GGNBP2-NEBLchr1734901666chr1021101869716IDDTLTVKYATAGACGACACCCTGACGGTAAAATAC
GGNBP2-NEBLchr1734901666chr1021101869816DDTLTVKYGACGACACCCTGACGGTAAAATAC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
GGNBP2-NEBLchr1734901666chr1021101869015RRQIPLYIDDTLTVKAGGAGGCAGATTCCCCTCTACATAGACGACACCCTGACGGTAAAA
GGNBP2-NEBLchr1734901666chr1021101869116RQIPLYIDDTLTVKYAGGCAGATTCCCCTCTACATAGACGACACCCTGACGGTAAAATAC
GGNBP2-NEBLchr1734901666chr10211018691025TLTVKYHEDFEKTKGACCCTGACGGTAAAATACCATGAAGATTTTGAAAAAACAAAGGGG
GGNBP2-NEBLchr1734901666chr1021101869217QIPLYIDDTLTVKYHCAGATTCCCCTCTACATAGACGACACCCTGACGGTAAAATACCAT
GGNBP2-NEBLchr1734901666chr1021101869318IPLYIDDTLTVKYHEATTCCCCTCTACATAGACGACACCCTGACGGTAAAATACCATGAA

Top

Information of the samples that have these potential fusion neoantigens of GGNBP2-NEBL

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
CESCGGNBP2-NEBLchr1734901666ENST00000304718chr1021101869ENST00000377122TCGA-C5-A3HD-01B

Top

Potential target of CAR-T therapy development for GGNBP2-NEBL

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to GGNBP2-NEBL

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to GGNBP2-NEBL

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource